Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00

Protagonist Therapeutics (NASDAQ:PTGX) had its target price boosted by Citizens Jmp from $102.00 to $112.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 26.81% from the company’s current price.

A number of other brokerages have also issued reports on PTGX. Barclays lifted their price target on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. increased their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Truist Financial boosted their price objective on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. Weiss Ratings cut Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Finally, Jefferies Financial Group increased their target price on Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $98.83.

Protagonist Therapeutics Trading Up 1.4%

NASDAQ:PTGX traded up $1.22 on Thursday, reaching $88.32. The stock had a trading volume of 26,657 shares, compared to its average volume of 717,310. The company has a 50-day moving average of $84.07 and a 200 day moving average of $76.51. The stock has a market cap of $5.52 billion, a P/E ratio of 142.39 and a beta of 2.26. Protagonist Therapeutics has a 12-month low of $35.95 and a 12-month high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. The business had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. On average, equities analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the sale, the chief financial officer directly owned 60,320 shares in the company, valued at approximately $5,014,401.60. This trade represents a 43.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,932,758.30. This trade represents a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 203,167 shares of company stock worth $16,889,199. 4.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

Several institutional investors have recently bought and sold shares of PTGX. Farallon Capital Management LLC boosted its stake in Protagonist Therapeutics by 0.4% during the 3rd quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock valued at $411,601,000 after purchasing an additional 24,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 27.2% during the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after buying an additional 1,156,461 shares in the last quarter. BVF Inc. IL increased its holdings in shares of Protagonist Therapeutics by 24.7% in the 2nd quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after purchasing an additional 636,026 shares during the period. State Street Corp lifted its position in Protagonist Therapeutics by 18.5% in the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after buying an additional 500,924 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.